AnaptysBio, Inc. (ANAB) Stock Grade

About AnaptysBio, Inc.'s fundamentals

AnaptysBio is a biotechnology company with a $1.5 billion market capitalization that demonstrated strong revenue growth of 157% year-over-year, indicating rapidly expanding commercial traction. Despite this impressive top-line growth, the company operates at a net loss with a -5.6% net margin, reflecting the typical cost structure of clinical-stage and early commercial biotech firms. Notably, the company generated positive free cash flow despite its accounting losses, suggesting operational efficiency in converting revenue into actual cash—a meaningful distinction for a development-stage biotech. The company does not pay a dividend.